UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35083 NOVANTA INC. (Exact name of registrant as specified in its charter) New Brunswick, Canada 98-0110412 (State or other jurisdiction of in ...

Novanta Inc. (NASDAQ:NOVT) Q4 2022 Results Conference Call March 1, 2023 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair and Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Brian Drab - William Blair Joseph Donahue - Baird Operator Good morning. My name is Keith, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Inc. 2022 Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35083 NOVANTA INC. (Exact name of registrant as specified in its charter) New Brunswick, Canada 98-0110412 (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics Changes - Novanta achieved record results in Q3 2022 with revenue of $223 million, representing a 25% year-over-year growth on a reported basis and 21% organic growth [9][10] - Adjusted EBITDA was $49 million, up 22% year-over-year, with adjusted diluted earnings per share of $0.81, an 8% increase compared to the previous year [10][26] - The company raised its full-year 2022 financial guidance due to strong year-to-date performance [10][34] Business Line Data and Key Metrics Changes - Advanced industrial markets saw a 33% year-over-year growth and 5% sequential growth, driven by demand in automation and robotics [13] - Medical applications grew 19% year-over-year and 6% sequentially, with strong orders in surgical robotics and minimally invasive surgery equipment [15] - The Photonics segment experienced a 28% year-over-year revenue growth, while the Vision segment grew 12% year-over-year [28][30] Market Data and Key Metrics Changes - Sales in Europe grew 15%, while the U.S. saw a 36% year-over-year increase [16] - China revenue grew 9% year-over-year, but excluding acquisitions, it was down double digits due to the microelectronics downturn [16] - The overall book-to-bill ratio for Novanta normalized to 0.91 in Q3, with a year-to-date book-to-bill of 1.12 [12] Company Strategy and Development Direction - Novanta is focused on medical and advanced industrial applications, capitalizing on long-term trends such as robotics and automation [11][22] - The company continues to invest in R&D, with a Vitality Index of about 25% of sales from new products launched in the last four years [17] - A recent acquisition of MPH Medical Devices aims to enhance manufacturing capacity and improve gross margins in the medical consumables segment [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience amid macroeconomic challenges, with a strong backlog of $626 million [11][12] - The company anticipates continued strength in medical applications, which are expected to offset weaknesses in microelectronics [33] - Management expects to exit 2022 with near-record backlog and accelerating demand trends in medical markets [34] Other Important Information - Adjusted gross profit for Q3 was $101.7 million, with a 46% adjusted gross margin, up from 45% in the previous year [24] - Operating cash flow was approximately $15 million, impacted by higher inventory purchases and accounts receivables [27] - The company expects gross margins in Q4 to exceed 46%, maintaining a target of 46% for the full year [36] Q&A Session Summary Question: Can you parse out the mix of consumables versus capital equipment in the Vision segment? - Both consumables and capital equipment had strong growth in Q3, but volatility may arise in Q4 due to labor shortages in hospital systems [43] Question: How do you view the current capacity of the new facility acquired? - The facility will require 2023 for production line transfers and qualification, with significant contributions expected in 2024 [47] Question: What is the expected impact of currency on Q4 revenue guidance? - Similar FX headwinds as experienced in Q3 are expected to be embedded in the Q4 guidance [48][51] Question: How is the Precision Motion segment expected to trend in Q4 and beyond? - The segment is expected to decline 8% to 10% in Q4 due to the Westwind product line, but Celera Motion and ATI businesses are expected to grow mid-single digits [63] Question: What is the outlook for the medical market in 2023? - The medical market is expected to grow collectively in 2023, offsetting weaknesses in microelectronics [56]

Novanta Inc. (NASDAQ:NOVT) Q2 2022 Results Earnings Conference Call August 9, 2022 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair and Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities, Inc. Brian Drab - William Blair Robert Mason - Robert W. Baird Andrew Buscaglia - Berenberg Capital Markets Operator Good morning. My name is Andrea and I will be your conference operator today. At this time, ...

Novanta A Trusted Technology Partner June 2022 Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with business and economic conditions, failure to achieve expected benefits of acquisitions, failure to comply with the Food and Drug Administration regulations, customer and/or suppl ...

Novanta Inc (NASDAQ:NOVT) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - CEO & Chairman of the Board Robert Buckley - CFO Conference Call Participants Lee Jagoda - CJS Securities Rob Mason - Baird Brian Drab - William Blair Andrew Buscaglia - Berenberg Operator Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Inc. 2022 First Quarte ...

Novanta Inc. (NASDAQ:NOVT) Q4 2021 Earnings Conference Call March 1, 2022 10:00 AM ET Company Participants Ray Nash ??? Corporate Finance Leader Matthijs Glastra ??? Chairperson and Chief Executive Officer Robert Buckley ??? Chief Financial Officer Conference Call Participants Lee Jagoda ??? CJS Securities Rob Mason ??? Baird Brian Drab ??? William Blair Andrew Buscaglia ??? Berenberg Operator Good morning. My name is Keith, and I will be your conference operator today. At this time, I would like to welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35083 NOVANTA INC. (Exact name of registrant as specified in its charter) New Brunswick, Canada 98-0110412 (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics Changes - In Q3 2021, Novanta reported approximately $178 million in revenue, representing a 24% year-over-year growth and 15% organic growth, marking the highest single-quarter sales in the company's history [8][10] - Adjusted EBITDA was $40 million, up 34% year-over-year, with an EBITDA margin of nearly 23%, an increase of 160 basis points year-over-year [9][10] - Adjusted diluted earnings per share increased by 79% year-over-year to $0.75 [10][35] Business Line Data and Key Metrics Changes - Medical applications accounted for 53% of total sales, growing 21% year-over-year and 7% sequentially [13][14] - Advanced industrial applications represented 47% of total sales, with a year-over-year growth of 28% and sequential growth of 5% [15] - The Photonics segment experienced a 19% year-over-year revenue increase, while the Precision Motion segment saw a 77% year-over-year growth [39][42] Market Data and Key Metrics Changes - Sales in China grew 28% year-over-year, while sales in Europe and the United States grew 20% and 27% respectively [16] - The overall book-to-bill ratio was 1.32, indicating strong demand across all segments [11] Company Strategy and Development Direction - The company closed the ATI and IMS acquisitions, which are expected to enhance its strategic positioning in high-growth markets [7][23] - Novanta's growth strategy includes expanding into new markets such as arthroscopy pumps and increasing R&D resources to capitalize on design wins [17][18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing supply chain challenges but expressed confidence in the company's ability to meet customer demand and maintain strong performance [12][26] - The company raised its guidance for the year, indicating optimism about long-term growth in both medical and industrial applications [26][45] Other Important Information - The company experienced a significant factory disruption at its Taunton facility, which impacted production and gross margins [29][31] - Despite supply chain issues, the company reported a healthy vitality index, with new product sales accounting for over 25% of total sales [19] Q&A Session Summary Question: Impact of the Taunton facility issue on revenue - The impact on organic growth was in the mid-single-digit range, approximately 4% to 7% [63] Question: Future gross margin expectations for the Photonics segment - Gross margins in Photonics are expected to remain flat in Q4 due to higher expenses associated with production [64] Question: Growth expectations for the ATI and IMS acquisitions - The ATI business is expected to grow mid- to high single digits, while IMS is anticipated to grow at a mid-single-digit rate [69][71] Question: DNA sequencing business outlook - The DNA sequencing business is expected to catch up to pre-pandemic levels, with strong growth driven by research lab reopenings and COVID variant sequencing [78][81] Question: Surgical market recovery expectations - Customers in the surgical market expect gradual recovery, with hospitals improving their handling of COVID cases and addressing patient backlogs [85]